Education
About Us
Working with TipRanks
Follow Us
HTEC - ETF AI Analysis
Top Page
ROBO Global Healthcare Technology and Innovation ETF (HTEC)
Rating:67Neutral
Price Target:―
Positive Factors
Broad Healthcare Innovation Focus
The fund targets a wide range of healthcare technology and innovation companies, giving investors exposure to a fast-evolving part of the health sector.
Many Strong-Performing Top Holdings
Most of the largest positions, including names like Moderna and several biotech and diagnostics firms, have shown strong gains this year, helping support the ETF’s recent performance.
Improving Recent Performance
The ETF has delivered solid gains over the past three months and year-to-date, suggesting positive momentum in its underlying holdings.
Negative Factors
High Sector Concentration
With almost all assets in healthcare and only a small slice in technology, the fund is heavily exposed to swings in a single sector.
Limited Geographic Diversification
The portfolio is dominated by U.S. companies, which reduces the benefits of international diversification and ties results closely to the U.S. market.
Relatively High Expense Ratio
The fund’s management fee is on the higher side for an ETF, which can gradually reduce net returns for long-term investors.
HTEC vs. SPDR S&P 500 ETF (SPY)
AUM51.92M
RegionGlobal
Expense Ratio0.68%
Beta0.95
IssuerROBO Global
Inception DateJun 25, 2019
Dividend Yield1.01%
Asset ClassEquity
Index TrackedROBO Global Healthcare Technology and Innovation ETF
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,445
30 Day Avg. Volume6,567
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
43.13Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering62
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HTEC Summary
HTEC is an ETF that follows the ROBO Global Healthcare Technology and Innovation index, focusing on companies using technology to improve healthcare. It holds firms involved in areas like medical robotics, telehealth, genetic testing, and AI in medicine. Well-known holdings include Moderna and Thermo Fisher. Someone might invest in HTEC to seek long-term growth from the rising use of advanced healthcare tools and to get a diversified basket of innovative health-tech companies in one fund. A key risk is that it is heavily focused on healthcare technology, so its price can swing more than the overall market.
How much will it cost me?The ROBO Global Healthcare Technology and Innovation ETF (HTEC) has an expense ratio of 0.68%, which means you’ll pay $6.80 per year for every $1,000 invested. This is higher than average because it is actively managed and focuses on a specialized niche in healthcare technology, requiring more research and expertise. It offers exposure to innovative companies in areas like medical robotics and genomic sequencing.
What would affect this ETF?HTEC could benefit from growing demand for healthcare innovation, driven by advancements in medical robotics, telehealth, and AI applications, as well as increased global focus on improving healthcare efficiency and outcomes. However, the ETF may face challenges from regulatory changes in healthcare technology, potential economic slowdowns impacting funding for innovation, or competition within the sector. Its global exposure and focus on cutting-edge companies position it well for long-term growth, but risks remain tied to sector-specific volatility.
HTEC Top 10 Holdings
HTEC is a pure play on global healthcare innovation, with nearly all its firepower in medical tech and biotech rather than broad market names. Recent strength from Twist Bioscience and AxoGen, both riding optimism around cutting-edge genetic tools and nerve repair, has helped pull the fund higher. Vertex and Stryker are steady anchors, adding dependable growth without much drama. On the flip side, Guardant Health and Arrowhead have been lagging, as investors worry about profitability and cash burn, leaving this high‑octane portfolio a bit bumpy but firmly pointed at the future of medicine.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Moderna | 2.83% | $1.44M | $22.01B | 55.00% | 59 Neutral | |
| Twist Bioscience | 2.43% | $1.24M | $2.96B | 31.65% | 43 Neutral | |
| Penumbra | 2.17% | $1.10M | $13.33B | 32.02% | 78 Outperform | |
| Vertex Pharmaceuticals | 2.10% | $1.07M | $117.08B | -7.83% | 78 Outperform | |
| Stryker | 2.09% | $1.06M | $140.03B | -1.13% | 70 Outperform | |
| Arrowhead Pharmaceuticals | 2.04% | $1.03M | $8.50B | 298.88% | 57 Neutral | |
| Regeneron | 2.03% | $1.03M | $82.62B | 4.94% | 78 Outperform | |
| Koninklijke Philips N.V. | 2.01% | $1.02M | €23.60B | -3.81% | 56 Neutral | |
| LivaNova | 1.98% | $1.01M | $3.39B | 67.64% | 63 Neutral | |
| Eurofins Scientific | 1.94% | $985.89K | €11.57B | 20.51% | 64 Neutral |
HTEC Technical Analysis
Negative
―
Price Trends
36.12
Negative
35.03
Negative
32.00
Positive
Market Momentum
-0.46
Positive
36.96
Neutral
18.20
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HTEC, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 35.20, equal to the 50-day MA of 36.12, and equal to the 200-day MA of 32.00, indicating a neutral trend. The MACD of -0.46 indicates Positive momentum. The RSI at 36.96 is Neutral, neither overbought nor oversold. The STOCH value of 18.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HTEC.
HTEC Peer Comparison
Comparison Results
Performance Comparison
HTEC
ROBO Global Healthcare Technology and Innovation ETF
33.70
5.97
21.53%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
GDOC
Goldman Sachs Future Health Care Equity ETF
―
―
―
LGHT
Langar Global HealthTech ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents